HER2 mutations have been found in non-small-cell lung cancers (NSCLC) and can direct treatment.

2024年6月7日 · The most meaningful type of HER2 mutation for treating lung cancer is called an exon 20 insertion. Who is most likely to have a HER2 oncogene? HER2 mutations tend to be more common in adenocarcinoma non-small cell lung cancer patients with little to …

Dr. Slamon’s team found that the HER2 protein is present at high levels (HER2 positive) in about 30 percent of breast cancers. They also discovered that high levels of HER2 are linked to a greater likelihood of metastasis and relapse and an overall decrease in patient survival.

About 15% to 20% of breast tumors have higher levels of a protein known as HER2. These cancers are called HER2-positive breast cancers. Ask your cancer care team about your HER2 status and what it means for you. What is HER2 and what does it mean? HER2 is a protein that helps breast cancer cells grow quickly.

Now known as zongertinib, our investigational HER2 TKI may specifically bind to the tyrosine kinase domain of both wild-type and mutated HER2 receptors, including difficult to target exon 20 insertion mutations.

2024年2月2日 · Mutations in HER2 are most commonly observed within the intracellular tyrosine kinase structural domain, encompassing exon 20 (20%), exon 19 (11%) and exon 21 (9%). The mutation hotspot varies across different types of cancer [ 6 ].

2024年7月11日 · HER2-activating mutations contribute to accelerated tumorigenesis and metastasis. This review provides an overview of HER2 biology, signaling pathways, mechanisms of dysregulation, and diagnostic approaches, as well as …

Our scientists discovered a highly selective and potent small molecule inhibitor of HER2. Zongertinib, our investigational HER2 tyrosine kinase inhibitor, is being developed as a potential oral treatment for people with NSCLC with a specific mutation in the HER2 gene.

2025年1月3日 · In NSCLC, de novo HER2 mutations are present in approximately 2% to 3% of patients. Next-generation sequencing [NGS] is required to identify those mutations. If we use PCR-based assays, there is a ...

2025年1月1日 · NSCLC is a heterogeneous disease driven by a wide spectrum of actionable mutations, with HER2 (ERBB2) identified as a driver in 2004.3,4. Currently, HER2 (ERBB2) is identified as an actionable biomarker by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). 1.